News
SWAV
328.26
+0.17%
0.56
Weekly Report: what happened at SWAV last week (0408-0412)?
Weekly Report · 1d ago
What's in Store for Abbott Laboratories (ABT) in Q1 Earnings?
NASDAQ · 3d ago
Pharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory News
NASDAQ · 3d ago
Guru Fundamental Report for SWAV
NASDAQ · 4d ago
5 Things To Know In Investing This Week - The Shockwave Takeover Issue
Shockwave Medical was in takeover talks with Johnson & Johnson. The company agreed to pay $335 per share in cash for Shockwave Medical. The purchasing managers index (PMI) came in hot this week. The CBO releases projections of the US debt to GDP are lies. DKI subscribers celebrated as the index came in high.
Benzinga · 4d ago
Johnson & Johnson Q1 Earnings Preview: Shockwave Could Be A Good Fit Despite Headwinds
Johnson & Johnson will report its first quarter 2024 results on Tuesday, April 16. Johnson & Johnson's stock has lagged the broader market over the last few years. The company announced the acquisition of Shockwave Medical, Inc. In March. In this earnings preview, I share my thoughts on JNJ's previous earnings and what can be expected from the upcoming report. I also discuss the company's acquisition-related track record and discuss the valuation of JNJ stock.
Seeking Alpha · 5d ago
Does Johnson & Johnson's Latest Acquisition Make It a No-Brainer Buy?
Johnson & Johnson is acquiring Shockwave Medical for $13.1 billion. The company has been focusing on acquisitions to strengthen its medtech and innovative medicines division. The healthcare giant's stock is down 8% in the past 12 months. Johnson & Johnson's acquisition of Shockwave does improve the company's growth prospects. But there's still more risk around the company.
The Motley Fool · 6d ago
Shockwave Medical Merges with Johnson & Johnson, Retains Key Leader
TipRanks · 6d ago
Shockwave Medical's (SWAV) Reducer Receives Positive Results
NASDAQ · 6d ago
3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade
NASDAQ · 04/09 08:21
Shockwave Medical Demonstrates Consistent, Results In 'Real-World' Study; Investigators Presented 6-Month Data From The Full Population Of The REDUCER-I Study, Alongside Interim Long-Term Follow-Up Results To 3-Years
Shockwave Medical, Inc. Presented six-month data from the REDUCER-I study. Results confirm the positive, 'real-world' outcomes of Shockwave Reducer. Reducer is a novel technology for the treatment of refractory angina. Six-month results demonstrated an improvement in angina symptoms in 70% of patients.
Benzinga · 04/08 20:05
SHOCKWAVE MEDICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Shockwave Medical, Inc. - SWAV
Former Attorney General of Louisiana Charles C. Foti, Jr. And the law firm of Kahn Swick & Foti are investigating the proposed sale of Shockwave Medical, Inc. To Johnson & Johnson. Under the terms of the proposed transaction, Shockwave shareholders will receive $335.00 in cash for each share. KSF is investigating whether the consideration undervalues the Company.
Barchart · 04/08 19:49
Shockwave Medical Cut to Neutral From Buy by CL King
Dow Jones · 04/08 18:38
Shockwave Medical Price Target Cut to $335.00/Share From $361.00 by Leerink Partners
Dow Jones · 04/08 18:35
Shockwave Medical Cut to Market Perform From Outperform by Leerink Partners
Dow Jones · 04/08 18:35
CL King Downgrades Shockwave Medical to Neutral
Benzinga · 04/08 18:28
Leerink Partners Downgrades Shockwave Medical to Market Perform, Lowers Price Target to $335
Benzinga · 04/08 18:24
Johnson & Johnson's $13B Shockwave Medical Deal Accelerates MedTech Strategy, Analyst Says
Johnson & Johnson agreed to acquire Shockwave Medical Inc. For $335 per share in cash. The acquisition is a strategic move to revamp Johnson & Johnson’s MedTech division. Goldman Sachs wrote that the company has invested $30 billion in M&A to strengthen its MedTech portfolio.
Benzinga · 04/08 17:27
Shockwave Medical Price Target Raised to $335.00/Share From $270.00 by Deutsche Bank
Dow Jones · 04/08 16:57
Shockwave Medical Cut to Hold From Buy by Deutsche Bank
Dow Jones · 04/08 16:57
More
Webull provides a variety of real-time SWAV stock news. You can receive the latest news about Shockwave Medical, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SWAV
Shockwave Medical, Inc. is a medical device company. The Company is primarily engaged in the development and commercialization of novel technologies that transform the care of patients with cardiovascular disease. The Company is focused on its intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular and heart valve disease. Built on a balloon catheter platform, the IVL technology uses lithotripsy to disrupt both superficial and deep vascular calcium., while minimizing soft tissue injury, and an integrated angioplasty balloon to dilate blockages at low pressures, restoring blood flow. Its Shockwave M5 IVL catheter and Shockwave M5+ IVL catheter are five-emitter catheters for use in its IVL System in medium-diameter vessels for the treatment of peripheral artery disease (PAD). Its Shockwave S4 IVL catheter is a four-emitter catheter for use in its IVL System in small-diameter vessels for the treatment of PAD.